FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults

Article Link: FDA Approves Nurtec ODT (rimegepant) for the Acute Treatment of Migraine in Adults

NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved Nurtec ODT (rimegepant) for the acute treatment of migraine in…

Source: FDA New Drug Approvals